A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naive Patients With Persistent Asthma.
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2013
At a glance
- Drugs BI 671800 (Primary) ; Fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
- 06 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Nov 2010 Additional trial locations (Estonia, Latvia) identified as reported by ClinicalTrials.gov.